Better Therapeutics Appoints Major General Elder Granger, M.D., U.S. Army (retired) to its Board of Directors
November 11 2021 - 8:00AM
Business Wire
Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX),
a prescription digital therapeutics company developing cognitive
behavioral therapy to address the root causes of cardiometabolic
diseases, today announced the appointment of Major General Elder
Granger, M.D., U.S. Army (retired) to its board of directors.
“Dr. Granger’s track record of leadership in navigating complex
policy, regulatory and competitive environments will be welcome
additions to the Better Therapeutics board,” said David Perry,
co-founder and chairman of Better Therapeutics. “His extensive
board experience coupled with an unwavering commitment to improving
the delivery of healthcare will be invaluable as we work to
establish our prescription digital therapeutics as the new standard
of care for people with cardiometabolic diseases.”
Dr. Granger joins Better Therapeutics’ board with decades of
experience in acquisition, operation and integration of managed
care programs within the Military Health System. He is currently
the president and CEO of The 5Ps, a healthcare, education and
leadership consulting organization. Prior to retiring from the U.S.
Army in 2009, he served as the Deputy Director and Program
Executive Officer of the TRICARE Management Activity, Office of the
Assistant Secretary of Defense (Health Affairs) in Washington, DC,
where he was the principal advisor to the Assistant Secretary of
Defense (Health Affairs) on Department of Defense health plan
policy and performance.
“Improving healthcare systems has been a major passion of mine
throughout my career, and Better Therapeutics is on the forefront
of developing innovative solutions that could truly change the
future of healthcare,” said Dr. Granger. “I’m eager to offer my
expertise in the healthcare space and help the team move its
prescription digital therapeutics towards commercialization to
reach more of the millions of people in the U.S. living with
cardiometabolic diseases.”
“Dr. Granger is a national treasure,” said Kevin Appelbaum,
co-founder and chief executive officer. “I’m honored by his
decision to serve on our board and, as a fellow veteran, look
forward to working closely with him to make our solutions
accessible to the more than 10 million veterans, active duty
service members and their families, who suffer a disproportionate
burden of cardiometabolic disease.”
Dr. Granger currently serves as an independent director and
Nominating & Governance Committee member for Cerner (NASDAQ:
CERN), an independent director and Chair of the Compliance
Committee for Cigna (NYSE: CI), and as an independent director of
DLH (NASDAQ: DLHC).
Boardspan Inc. served as an advisor to Better Therapeutics in
this appointment.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines. For more information visit:
bettertx.com
BTTX-PR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211111005472/en/
Heidi Chokeir, Ph.D. heidi.chokeir@canalecomm.com +1 619 203
5391
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jul 2023 to Jul 2024